FDALabel for drug repurposing studies and beyond
- 24 November 2020
- journal article
- letter
- Published by Springer Science and Business Media LLC in Nature Biotechnology
- Vol. 38 (12), 1378-1379
- https://doi.org/10.1038/s41587-020-00751-0
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicineDrug Discovery Today, 2020
- Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) InfectionJAMA Network Open, 2020
- Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialInternational Journal of Antimicrobial Agents, 2020
- 2019 FDA drug approvalsNature Reviews Drug Discovery, 2020
- Opioid and Benzodiazepine Coprescribing in the United States Before and After US Food and Drug Administration Boxed WarningJAMA Psychiatry, 2019
- Promoting Pediatric Drug Research and Labeling — Outcomes of LegislationNew England Journal of Medicine, 2019
- Drug repurposing: progress, challenges and recommendationsNature Reviews Drug Discovery, 2018
- FDA drug labeling: rich resources to facilitate precision medicine, drug safety, and regulatory scienceDrug Discovery Today, 2016
- Clinical Evidence Supporting Pharmacogenomic Biomarker Testing Provided in US Food and Drug Administration Drug LabelsJAMA Internal Medicine, 2014